Design,conduct,and analyses of Breast International Group (BIG) 1-98: A randomized,double-blind,phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive,early breast cancer

Abstract

Background Aromatase inhibitors provide superior disease control when compared with tamoxifen as adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer.

Purpose To present the design, history, and analytic challenges of the Breast International Group (BIG) 1-98 trial: an international, multicenter, randomized, double-blind, phase-III study comparing the aromatase inhibitor letrozole with tamoxifen in this clinical setting.

Methods From 1998—2003, BIG 1-98 enrolled 8028 women to receive monotherapy with either tamoxifen or letrozole for 5 years, or sequential therapy of 2 years of one agent followed by 3 years of the other. Randomization to one of four treatment groups permitted two complementary analyses to be conducted several years apart. The first, reported in 2005, provided a head-to-head comparison of letrozole versus tamoxifen. Statistical power was increased by an enriched design, which included patients who were assigned sequential treatments until the time of the treatment switch. The second, reported in late 2008, used a conditional landmark approach to test the hypothesis that switching endocrine agents at approximately 2 years from randomization for patients who are disease-free is superior to continuing with the original agent. Results The 2005 analysis showed the superiority of letrozole compared with tamoxifen. The patients who were assigned tamoxifen alone were unblinded and offered the opportunity to switch to letrozole. Results from other trials increased the clinical relevance about whether or not to start treatment with letrozole or tamoxifen, and analysis plans were expanded to evaluate sequential versus single-agent strategies from randomization.

Limitations Due to the unblinding of patients assigned tamoxifen alone, analysis of updated data will require ascertainment of the influence of selective crossover from tamoxifen to letrozole.

Conclusions BIG 1-98 is an example of an enriched design, involving complementary analyses addressing different questions several years apart, and subject to evolving analytic plans influenced by new data that emerge over time.

Get full access to this article

View all access options for this article.

References

World Health Organization , GLOBOCAN 2002: Cancer incidence, mortality, and prevalence worldwide Available at: http://www.dep.iarc.fr. Accessed 6 March 2008.

Early Breast Cancer Trialists' Cooperative Group. Effects of chemotherapy and hormone therapy on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1687-1717.

Smith IE , Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348: 2431-42.

Mouridsen H. , Gershanovich M. , Sun Y. , et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for post menopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606 [Erratum, J Clin Oncol 2001 ; 19: 3302.].

Mouridsen H. , Gershanovich M. , Sun Y. , et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in post-menopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101-09.

Ingle IN , Dowsett M. , Cuzick J. , et al. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor-positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies (abstract). Cancer Res 2009; 69(Suppl. 2): 12.

Northrop Grumman Corporation: MedDRA. Available at: http://meddramsso.com.

The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in post-menopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-57.

Coates AS , Keshaviah A. , Thurlimann B. , et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for post-menopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2005 ; 25: 486-92.

10.

Anderson JR , Cain KC , Gelber RD Analysis of survival by tumor response . J Clin Oncol 1983; 1: 710-19.

11.

Coombes RC , Hall E. , Gibson LJ , et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in post-menopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1892. Erratum in: N Engl J Med 2004; 351: 2461. N Engl J Med 2006; 355:1746. van de Velde, Cornelius [added].

12.

Viale G. , Regan MM , Maiorano E. , et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for post-menopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25: 3846-52.

13.

Viale G. , Giobbie- Hurder A. , Regan MM , et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in post-menopausal women with endocrine-responsive breast cancer: results from trial BIG 1-98 comparing adjuvant endocrine therapy with tamoxifen versus letrozole. J Clin Oncol 2008; 26(34): 5569-75.

14.

Rasmussen BB , Regan MM , Lykkesfeldt AE , et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for post-menopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008; 9: 23-28.